Previous close | 10.11 |
Open | 9.98 |
Bid | 10.45 x 1200 |
Ask | 10.87 x 3000 |
Day's range | 9.94 - 10.95 |
52-week range | 5.42 - 22.63 |
Volume | |
Avg. volume | 2,534,141 |
Market cap | 2.999B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 16.54 |
EPS (TTM) | 0.64 |
Earnings date | 28 Mar 2022 - 01 Apr 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 31.13 |
VANCOUVER, British Columbia, June 29, 2022--AbCellera (Nasdaq: ABCL) today announced that Eli Lilly and Company (Lilly) has entered into a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab, the second antibody developed through AbCellera’s collaboration with Lilly, for approximately $275 million. The existing U.S. government supply of bebtelovimab, including the new purchase, is expected to meet present demand through late August 2022. Del
Insiders who bought AbCellera Biologics Inc. ( NASDAQ:ABCL ) stock in the last 12 months were richly rewarded last...
AbCellera Biologics Inc. (ABCL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.